Lyme borreliosis

Lancet Infectious Diseases

Volumn 3, Issue 8, 2003, Pages 489-500

  Hengge, Ulrich R ^a   Tannapfel, Andrea ^c   Tyring, Steven K ^b   Erbel, Raimund ^c   Arendt, Gabriele ^a   Ruzicka, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CHIMERIC PROTEIN; LYME DISEASE VACCINE; RECOMBINANT PROTEIN;

ACRODERMATITIS; ANTIBODY DETECTION; ARTHRITIS; BACTERIUM CULTURE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; CARDITIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOBLOTTING; LYME DISEASE; LYMPHOCYTOMA; NEUROBORRELIOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SPECIES DIFFERENCE; WESTERN HEMISPHERE;

EID: 0042206872     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00722-9     Document Type: Review

References (121)

1. Bosler EM, Coleman JL, Benach JL, et al. Natural distribution of the Ixodes dammini spirochete. Science 1983; 220: 321-22.
2. Pena CA, Strickland GT. Incidence rates of Lyme disease in Maryland: 1993 through 1996. Md Med J 1999; 48: 68-73.
3. Huppertz HI, Bohme M, Standaert SM, Karch H, Plotkin SA. Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol Infect Dis 1999; 18: 697-703.
4. Stanek G, Satz N, Strle F, Wilske B. Epidemiology of Lyme borreliosis. In: Weber K, Burgdorfer W, eds. Aspects of Lyme borreliosis. Berlin, Springer-Verlag: 1993: 358-70.
5. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998; 339: 216-22.
6. Lane RS, Piesman J, Burgdorfer W. Lyme borreliosis: relation of its causative agent to its vectors and hosts in North America and Europe. Annu Rev Entomol 1991; 36: 587-609.
7. Orloski KA, Hayes EB, Campbell GL, Dennis DT. Surveillance for Lyme disease - United States, 1992-1998. MMWRCDC Surveill Summ 2000; 49: 1-11.
8. Piesman J. Dynamics of Borrelia burgdorferi transmission by nymphal Ixodes dammini ticks. J Infect Dis 1993; 167: 1082-85.
9. Ohnishi J, Piesman J, de Silva AM. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc Natl Acad Sci USA 2001; 98: 670-75.
10. Baranton G, Postic D, Saint Girons I, et al. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii nov, and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol 1992; 42: 378-83.
11. Parola P, Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis 2001; 32: 897-928.
12. Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 1984; 57: 521-25.
13. Barbour AG, Hayes SF. Biology of Borrelia species. Microbiol Rev 1986; 50: 381-400.
14. de Silva AM, Fikrig E. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J Clin Invest 1997; 99: 377-79.
15. Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997; 390: 580-86.
16. Liang FT, Nelson FK, Fikrig E. Molecular adaptation of Borrelia burgdorferi in the murine host. J Exp Med 2002; 196: 275-80.
17. Liang FT, Jacobs MB, Bowers LC, Philipp MT. An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. J Exp Med 2002; 195: 415-22.
18. Hodzic E, Feng S, Freet KJ, Borjesson DL, Barthold SW. Borrelia burgdorferi population kinetics and selected gene expression at the host-vector interface. Infect Immun 2002; 70: 3382-88.
19. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci USA 1995; 92: 2909-13.
20. Revel AT, Talaat AM, Norgard MV. DNA microarray analysis of differential gene expression in Borrelia burgdorferi, the Lyme disease spirochete. Proc Natl Acad Sci USA 2002; 99: 1562-67.
21. Weis JJ, McCracken BA, Ma Y, et al. Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease. J Immunol 1999; 162: 948-56.
22. Hirschfeld M, Kirschning CJ, Schwandner R, et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999; 163: 2382-86.
23. Mullegger RR, McHugh G, Ruthazer R, Binder B, Kerl H, Steere AC. Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 2000; 115: 1115-23.
24. Krause A, Brade V, Schoerner C, Solbach W, Kalden JR, Burmester GR. T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum 1991; 34: 393-402.
25. Akin E, McHugh GL, Flaven RA, Fikrig E, Steere AC. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect Immun 1999; 67: 173-81.
26. Aberer E, Koszik F, Silberer M. Why is chronic Lyme borreliosis chronic? Clin Infect Dis 1997; 25: S64-70.
27. Kraiczy P, Skerka C, Kirschfink M, Zipfel PF, Brade V. Immune evasion of Borrelia burgdorferi: insufficient killing of the pathogens by complement and antibody. Int J Med Microbiol 2002; 291: 141-46.
28. Buchner SA, Rufli T. Erythema chronicum migrans: evidence for cellular immune reaction in the skin lesion. Dermatologica 1987; 174: 144-49.
29. Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol 1991; 13: 334-41.
30. Glatzel A, Entschladen F, Zollner TM, et al. The responsiveness of human V delta 1 gamma delta T cells to Borrelia burgdorferi is largely restricted to synovial-fluid cells from patients with Lyme arthritis. J Infect Dis 2002; 186: 1043-46.
31. van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis 1991; 77: 81-84.
32. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. N Engl J Med 1996; 335: 1270-74.
33. Nadelman RB, Wormser GP. Lyme borreliosis. Lancet 1998; 352: 557-65.
34. Hassler D, Maiwald M. Reinfection with Borrelia burgdorferi in an immunocompetent patient. Dtsch Med Wochenschr 1994; 119: 338-42.
35. Maraspin V, Lotric-Furlan S, Strle F. Development of erythema migrans in spite of treatment with antibiotics after a tick bite. Wien Klin Wochenschr 2002; 114: 616-19.
36. van Dam AP, Kuiper H, Vos K, et al. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis 1993; 17: 708-17.
37. Picken RN, Strle F, Ruzic-Sabljic E, et al. Molecular subtyping of Borrelia burgdorferi sensu lato isolates from five patients with solitary lymphocytoma. J Invest Dermatol 1997; 108: 92-97.
38. Stanek G, O'Connell S, Cimmino M, et al. European Union concerted action on Risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 1996; 108: 741-47.
39. Asbrink E, Hovmark A. Successful cultivation of spirochetes from skin lesions of patients with erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Acta Pathol Microbiol Immunol Scand [B] 1985; 93: 161-63.
40. Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 1996; 275: 1657-60.
41. Nadelman RB, Horowitz HW, Hsieh TC, et al. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med 1997; 337: 27-30.
42. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100: 502-08.
43. Steere AC. Lyme disease. N Engl J Med 1989; 321: 586-96.
44. Mikkila HO, Seppala IJ, Viljanen MK, Peltomaa MP, Karma A. The expanding clinical spectrum of ocular lyme borreliosis. Ophthalmology 2000; 107: 581-87.
45. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Treatment of erythema migrans in pregnancy. Clin Infect Dis 1996; 22: 788-93.
46. Anon. Case definitions for infectious conditions under public health surveillance: Lyme disease. MMWR Morb Mortal Wkly Rep 1997; 46: 20-21.
47. Hunfeld KP, Allwinn R, Peters S, Kraiczy P, Brade V. Serologic evidence for tick-borne pathogens other than Borrelia burgdorferi (TOBB) in Lyme borreliosis patients from midwestern Germany. Wien Klin Wochenschr 1998; 110: 901-08.
48. Telford SR 3rd, Armstrong PM, Katavolos P, et al. A new tick-borne encephalitis-like virus infecting New England deer ticks, Ixodes dammini. Emerg Infect Dis 1997; 3: 165-70.
49. van der Linde MR, Ballmer PE. Lyme carditis. In: Weber K, Burgdorfer W, Schierz G, eds. Aspects of Lyme borreliosis. Berlin: Springer-Verlag, 1993: 131-45.
50. Nagi KS, Joshi R, Thakur RK. Cardiac manifestations of Lyme disease: a review. Can J Cardiol 1996; 12: 503-06.
51. Stanek G, Klein J, Bittner R, Glogar D. Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy. N Engl J Med 1990; 322: 249-52.
52. Sonnesyn SW, Diehl SC, Johnson RC, Kubo SH, Goodman JL. A prospective study of the seroprevalence of Borrelia burgdorferi infection in patients with severe heart failure. Am J Cardiol 1995; 76: 97-100.
53. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323: 1438-44.
54. State of Connecticut Department of Public Health. Lyme disease update. Conn Epidemiol 1993; 13: 9.
55. Oschmann P, Dorndorf W, Hornig C, Schafer C, Wellensiek HJ, Pflughaupt KW. Stages and syndromes of neuroborreliosis. J Neurol 1998; 245: 262-72.
56. Scheid R, Hund-Georgiadis M, von Cramon DY. Intracerebral haemorrhage as a manifestation of Lyme neuroborreliosis? Eur J Neurol 2003; 10: 99-101
57. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999; 180: 377-83.
58. Hemmer B, Gran B, Zhao Y, et al. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med 1999; 5: 1375-82.
59. Roberts ED, Bohm RP Jr, Lowrie RC Jr, et al. Pathogenesis of Lyme neuroborreliosis in the rhesus monkey: the early disseminated and chronic phases of disease in the peripheral nervous system. J Infect Dis 1998; 178: 722-32.
60. Cadavid D, O'Neill T, Schaefer H, Pachner AR. Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of lyme disease. Lab Invest 2000; 80: 1043-54.
61. Steere AC, Gross D, Meyer AL, Huber BT. Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. J Autoimmun 2001; 16: 263-68.
62. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107: 725-31.
63. Steere AC, Duray PH, Butcher EC. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 1988; 31: 487-95.
64. Steere AC, Malawista SE, Hardin JA, Ruddy S, Askenase W, Andiman WA. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977; 86: 685-98.
65. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330: 229-34.
66. Vincent MS, Roessner K, Sellati T, et al. Lyme arthritis synovial gamma delta T cells respond to Borrelia burgdorferi lipoproteins and lapidated hexapeptides. J Immunol 1998; 161: 5762-71.
67. Gross DM, Steere AC, Huber BT. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol 1998; 160: 1022-28.
68. Yin Z, Braun J, Neure L, et al. T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum 1997; 40: 69-79.
69. Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878-88.
70. Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998; 281: 703-06.
71. Meyer AL, Trollmo C, Crawford F, et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class 11 tetramers. Proc Natl Acad Sci USA 2000; 97: 11433-38.
72. Trollmo C, Meyer AL, Steere AC, Hafler DA, Huber BT. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1 alpha L is a partial agonist for outer surface protein A-reactive T cells. J Immunol 2001; 166: 5286-91.
73. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001; 2: 797-801.
74. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297: 1689-92.
75. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 1993; 61: 2774-79.
76. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum 1999; 42: 1813-22.
77. Tugwell P, Dennis DT, Weinstein A, et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997; 127: 1109-23.
78. Asbrink E, Hovmark A, Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986; 263: 253-61.
79. Lebech AM. Polymerase chain reaction in diagnosis of Borrelia burgdorferi infections and studies on taxonomic classification. APMIS Suppl 2002; 105: 1-40.
80. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269: 1812-16.
81. Jespersen DJ, Smith TF, Rosenblatt JE, Cockerill FR 3rd. Comparison of the Borrelia DotBlot G, MarDx, and VIDAS enzyme immunoassays for detecting immunoglobulin G antibodies to Borrelia burgdorferi in human serum. J Clin Microbiol 2002; 40: 4782-84.
82. Norman GL, Antig JM, Bigaignon G, Hogrefe WR. Serodiagnosis of Lyme horreliosis by Borrelia burgdorferi sensu stricto, B garinii, and B afzelii western blots (immunoblots). J Clin Microbiol 1996; 34: 1732-38.
83. Lomholt H, Lebech AM, Hansen K, Brandrup F, Halkier-Sorensen L. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Acta Derm Venereol 2000; 80: 362-66.
84. Panelius J, Seppala I, Granlund H, Nyman D, Wahlberg P. Evaluation of treatment responses in late Lyme borreliosis on the basis of antibody decrease during the follow-up period. Eur J Clin Microbiol Infect Dis 1999; 18: 621-29.
85. Gomes-Solecki MJ, Dunn JJ, Luft BJ, et al. Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease. J Clin Microbiol 2000; 38: 2530-35.
86. Gomes-Solecki MJ, Wormser GP, Schriefer M, et al. Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status. J Clin Microbiol 2002; 40: 193-97.
87. Kharitonenkov IG, Pomelova VG, Bucher DJ, et al. Epitope mapping of the outer surface protein A (OspA) of the spirochete Borrelia burgdorferi using a panel of monoclonal antibodies and lanthanide competition fluoroimmunoassay. Biochemistry (Mosc) 2002; 67: 640-50.
88. Robertson J, Guy E, Andrews N, et al. A European multicenter study of immunoblotting in serodiagnosis of lyme borreliosis. J Clin Microbiol 2000; 38: 2097-102.
89. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993; 167: 392-400.
90. Steere AC, Berardi VP, Weeks KE, Logigian EL, Ackermann R. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. J Infect Dis 1990; 161: 1203-09.
91. Nichol G, Dennis DT, Steere AC, et al Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1998; 128: 37-48.
92. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000; 31: 1-14.
93. Williams CL, Strobino B, Weinstein A, Spierling P, Medici F. Maternal Lyme disease and congenital malformations: a cord blood serosurvey in endemic and control areas. Paediatr Perinat Epidemiol 1995; 9: 320-30.
94. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 697-704.
95. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990; 336: 1404-06.
96. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117: 273-80.
97. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-91.
98. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997; 337: 289-94.
99. Nowakowski J, McKenna D, Nadelman RB, et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000; 9: 563-67.
100. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994; 44: 1203-07.
101. Pfister HW, Preac-Mursic V, Wilske B, Einhaupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol 1989; 46: 1190-94.
102. Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg AS, Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 1996; 40: 1104-07.
103. Phillips SE, Mattman LH, Hulinska D, Moayad H. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection 1998; 26: 364-67.
104. Oksi J, Marjamaki M, Nikoskelainen J, viljanen MK. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med 1999; 31: 225-32.
105. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1: 1191-94.
106. Dinerman H, Steere AC. Lyme disease associated with fibromyalgia. Ann Intern Med 1992; 117: 281-85.
107. Shadick NA, Phillips CB, Sangha O, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999; 131: 919-26.
108. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED. Long-term outcomes of persons with Lyme disease. JAMA 2000; 283: 609-16.
109. Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10-20-year follow-up. J Infect Dis 2001; 183: 453-60.
110. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92.
111. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327: 1769-73.
112. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycydine for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79-84.
113. Recommendations for the use of Lyme disease vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 1999; 48: 1-17, 21-25.
114. Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med 1992; 327: 534-41.
115. Fix AD, Strickland GT, Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. JAMA 1998; 279: 206-10.
116. Warshafsky S, Nowakowski J, Nadelman RB, Kamer RS, Peterson SJ, Wormser GP. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med 1996; 11: 329-33.
117. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998; 339: 209-15.
118. Schoen RT, Sikand VK, Caldwell MC, et al. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clin Ther 2000; 22: 315-25.
119. Schoen RT, Deshefy-Longhi T, Van-Hoecke C, Buscarino C, Fikrig E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clin Ther 2003; 25: 210-24.
120. Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. Pediatrics 1998; 102: 905-08.
121. Nadelman RB, Herman E, Wormser GP. Screening for Lyme disease in hospitalized psychiatric patients: prospective serosurvey in an endemic area. Mt Sinai J Med 1997; 64: 409-12.